Can Naren Hospital in Thailand Perform Third-Generation IVF? Detailed Explanation of PGT Technology Qualifications and Process
AI Summary
AI Summary: Naren Hospital in Thailand has the qualifications and hardware conditions to perform third-generation IVF (Preimplantation Genetic Testing, PGT). The hospital offers three main types: PGT-A (aneuploidy screening), PGT-M (monogenic disease testing), and PGT-SR (chromosomal structural rearrangement testing). Applicable populations include advanced maternal age women, those with recurrent miscarriage, carriers of chromosomal abnormalities, and families with known monogenic diseases. In the process, after routine in vitro fertilization, a biopsy is performed when the embryo develops into a blastocyst on day 5-6. After laboratory genetic analysis, embryos with normal chromosomes or without pathogenic genes are selected for transfer. It is recommended that patients complete genetic counseling and preoperative examinations before starting the cycle.
Beginning of the main text: Real consultation scenario
"Doctor, my husband and I are both carriers of thalassemia. We have consulted several reproductive centers domestically and heard that Naren Hospital in Thailand can perform third-generation IVF to screen for healthy embryos. Is this true? How does it work specifically?" This is a common type of consultation I encounter in the reproductive genetics clinic. People who ask this question have usually already undergone basic genetic testing and have a clear understanding of their genetic risks, but still have information gaps when choosing technical paths and medical institutions. The following breaks down the real situation of third-generation IVF at Naren Hospital from four dimensions: technical qualifications, applicable conditions, process milestones, and common blind spots.
Direct Answer: Does Naren Hospital Have the Qualifications for Third-Generation IVF?
The Assisted Reproductive Center at Naren Hospital in Thailand has the technical capability and laboratory conditions to perform Preimplantation Genetic Testing (PGT, i.e., third-generation IVF). The hospital offers the following three main types of PGT services:
| Technology Type | Testing Target | Example Applicable Scenarios |
|---|---|---|
| PGT-A | Screening for embryonic chromosomal aneuploidy | Advanced maternal age (≥38 years), recurrent implantation failure, recurrent miscarriage |
| PGT-M | Testing for monogenic diseases | Thalassemia, Spinal Muscular Atrophy (SMA), hereditary deafness, etc. |
| PGT-SR | Testing for chromosomal structural rearrangements | Carriers of balanced translocations, Robertsonian translocations, inversions |
It is important to clarify that the core value of third-generation IVF is "screening," not "treatment." It cannot change the genetic status of the embryo itself; it can only help select embryos with normal chromosomes or without pathogenic genes for transfer. The genetics laboratory at Naren Hospital uses a Next-Generation Sequencing (NGS) platform, which can simultaneously cover aneuploidy screening of all 24 chromosomes and testing for known monogenic disease loci.
Doctor's Perspective: Third-Generation IVF is Not for Everyone
As a reproductive specialist, I often encounter situations where people consider third-generation IVF as a "more advanced IVF." This is a cognitive bias that needs clarification.
When is third-generation IVF suitable?
- One or both partners are confirmed carriers or patients of a monogenic disease;
- Female age ≥ 38 years, or a history of 2 or more unexplained miscarriages;
- One partner has a chromosomal structural abnormality (e.g., balanced translocation, Robertsonian translocation);
- Previous IVF cycles with recurrent implantation failure (≥3 transfers of good quality embryos without pregnancy);
- Families requiring simultaneous HLA typing (to create a savior sibling).
When is it unsuitable or requires caution?
- Young women (≤35 years, no miscarriage history) solely seeking "improved success rates" without clear genetic indications;
- Very low ovarian reserve (AMH < 0.5 ng/mL, antral follicle count < 3), where the number of retrieved eggs may be insufficient to form blastocysts for biopsy;
- Families with ethical or religious concerns about embryo biopsy and no clear genetic risk;
- Before completing genetic counseling and the informed consent process.
In clinical practice at Naren Hospital, doctors arrange a complete genetic counseling session before starting the cycle, explaining in detail the benefits, limitations, and potential risks of PGT (such as an embryo damage rate of about 1-2% after biopsy, and the possibility of false negatives or false positives due to embryonic mosaicism).
Actual Process: Steps for Third-Generation IVF at Naren Hospital
Below is the standardized PGT cycle process, typically taking 8-12 weeks from the initial consultation to transfer (depending on the genetic testing cycle).
- Initial Consultation and Genetic Counseling (1st visit): Both partners complete fertility assessments (AMH, FSH, LH, antral follicle count, semen analysis) and submit previous genetic test reports or chromosomal karyotype analysis results. The doctor confirms PGT indications and formulates a testing plan.
- Preoperative Examinations and Record Creation: Includes infectious disease screening (HIV, Hepatitis B, Hepatitis C, Syphilis), blood type, coagulation function, thyroid function, uterine cavity assessment, etc. The male partner must complete a routine semen analysis and sperm morphology assessment. A treatment record is created once all examination reports are complete.
- Ovarian Stimulation and Egg Retrieval: An individualized stimulation protocol (antagonist or long protocol) is designed based on the woman's ovarian function. Egg retrieval is performed under intravenous anesthesia, lasting about 15-20 minutes.
- Fertilization and Blastocyst Culture: ICSI (Intracytoplasmic Sperm Injection) is used for fertilization to avoid interference from sperm-borne genetic material in the test results. Embryos are cultured until they form blastocysts on day 5-6.
- Blastocyst Biopsy and Genetic Testing: 3-5 cells are taken from the trophectoderm of the blastocyst for testing. The biopsied blastocyst is immediately cryopreserved. The testing cycle typically takes 2-4 weeks.
- Frozen Embryo Transfer (FET): Based on the test results, a blastocyst with normal chromosomes or without the pathogenic gene is selected. The endometrium is prepared in a natural or artificial cycle before transfer. A blood test for HCG is done 12-14 days after transfer to confirm pregnancy.
Easily Overlooked Details: Key Points in Third-Generation IVF
Based on actual cases, the following details are often overlooked by patients but have a direct impact on cycle outcomes:
- Narrow biopsy window: Blastocyst biopsy must be performed on day 5-6. Doing it too early or too late affects embryo survival and test accuracy. This makes the experience of the laboratory team and the stability of the embryo culture system critical.
- Mosaicism issue: About 3-5% of blastocysts exhibit chromosomal mosaicism (coexistence of normal and abnormal cells). The genetics laboratory at Naren Hospital clearly indicates the mosaicism percentage in the report. The clinician must decide on transfer based on the type and percentage of mosaicism.
- Freeze-thaw loss: Biopsied blastocysts undergo a freeze-thaw process, carrying a risk of about 5-10% reduction in survival rate. This is not unique to Naren Hospital but a common industry phenomenon.
- PGT-M requires a proband sample: For monogenic disease testing, a blood sample from an affected child (proband) or both partners is usually needed for family validation; otherwise, the pathogenic locus cannot be located. Many families realize this only after starting the cycle, causing delays.
Common Pitfalls: Mismatch Between Perception and Expectation
The following three misconceptions are most frequently encountered in clinical consultations:
Misconception 1: "After third-generation IVF, the embryo is definitely fine."
Fact: PGT cannot detect all genetic diseases, nor can it rule out genetic mutations that may occur during later embryonic development. PGT-A has a detection rate for chromosomal aneuploidy > 95%, but there is still a false negative rate of about 1-2%.
Misconception 2: "Third-generation IVF has a 100% success rate."
Fact: PGT can only screen embryos; it cannot guarantee implantation or live birth after transfer. The final live birth rate is still influenced by factors such as the uterine environment, maternal immune status, and endocrine levels. Data from Naren Hospital (based on industry averages) shows a live birth rate per single PGT cycle of about 55-65% for women under 35, dropping to 25-35% for those over 40.
Misconception 3: "Preoperative examinations are not needed for third-generation IVF in Thailand."
Fact: Naren Hospital strictly adheres to international assisted reproduction standards. All patients must complete a full set of preoperative examinations before starting a cycle, including infectious disease screening, chromosomal karyotype analysis, and hysteroscopy assessment. Records cannot be created if examinations are missing.
Differences by Age Group: Impact of Age on PGT Strategy
| Female Age | Primary Genetic Risk Type | Recommended PGT Strategy | Expected Number of Eggs Retrieved |
|---|---|---|---|
| ≤ 35 years | Monogenic disease / Chromosomal structural abnormality | PGT-M or PGT-SR | 10-15 |
| 36-39 years | Increased aneuploidy risk + Genetic disease | PGT-A combined with PGT-M (if needed) | 7-12 |
| ≥ 40 years | Significantly increased aneuploidy risk | PGT-A prioritized, consider egg donation | 3-7 |
The most significant change with advancing age is the increase in embryonic aneuploidy rate. The euploidy rate for blastocysts in women over 40 is typically below 30%, meaning that even after PGT-A, there may be no transferable embryos. Reproductive specialists at Naren Hospital will clearly inform patients of the possibility of "no transferable embryos" before starting, based on age and ovarian reserve.
Case Scenario Analysis: Decision Path for Thalassemia Carriers
Process Review: After one ovarian stimulation cycle, 14 eggs were retrieved. Following ICSI fertilization, 8 blastocysts formed. After biopsy and testing, 3 blastocysts were found to be chromosomally normal and did not carry the pathogenic gene (euploid and without the --SEA mutation). The first transfer resulted in a successful pregnancy, and mid-trimester amniocentesis confirmed the PGT diagnosis.
Key Decision Point: The success of this case hinged on the couple completing family validation in advance (providing blood samples from both sets of parents for linkage analysis), allowing the PGT-M probe design to be ready before starting the cycle. If validation had been initiated only after egg retrieval, the testing cycle would have been extended by 4-6 weeks, with a risk of being unable to distinguish between the pathogenic and normal genes.
Special Situations: Who Needs Additional Preparation
The following groups require additional procedures or materials when undergoing third-generation IVF at Naren Hospital:
- History of recurrent implantation failure: It is recommended to complete endometrial microbiome testing (EMT) and chronic endometritis screening (CD138 immunohistochemistry) before starting the cycle. About 30% of recurrent implantation failure is related to abnormal endometrial microenvironment, which PGT cannot address.
- Male factor combined with genetic abnormalities: Such as Y chromosome microdeletion (AZF deletion) or Klinefelter syndrome (47,XXY). Genetic counseling and male endocrine evaluation are needed simultaneously. PGT-SR can screen for chromosomally normal embryos but cannot improve sperm production capacity.
- Need to use donor eggs or sperm: Naren Hospital requires recipients of donor eggs/sperm to complete separate genetic and psychological counseling and sign informed consent. PGT-A is usually not necessary in donor egg cycles but can be chosen.
- Previous pregnancy with fetal abnormalities: Tissue samples or amniotic fluid cells from the abnormal fetus must be collected for genetic validation; otherwise, the PGT-M probe design may lack critical controls.
Answers to Frequently Asked Questions
Q: What materials are needed for third-generation IVF at Naren Hospital?
A: Passports of both partners (valid for ≥ 6 months), all previous examination reports (genetic tests, chromosomal karyotypes, surgical records, etc.), marriage certificate (e.g., translated copy), and genetic counseling records. If PGT-M is involved, blood samples from the proband or family members must be submitted simultaneously.
Q: How long does it take from the initial consultation to transfer?
A: The minimum is about 8 weeks (excluding the time for genetic testing probe design). If PGT-M requires custom probe design, an additional 4-6 weeks is needed. It is recommended to allow a total of 12-14 weeks.
Q: What is the approximate cost of third-generation IVF?
A: At Naren Hospital, the cost of a complete PGT cycle (including ovarian stimulation, egg retrieval, ICSI, blastocyst culture, biopsy, genetic testing, and one transfer) is approximately USD 9,000 - 14,000, depending on the type of testing (PGT-A costs less than PGT-M) and medication dosage. The cost does not include preoperative examinations, hysteroscopy, or additional embryo freezing fees.
Q: If the first transfer fails, are there frozen embryos available for use?
A: If there were surplus euploid blastocysts cryopreserved from the previous cycle, a subsequent FET can be arranged directly. If no embryos remain, a new ovarian stimulation cycle and PGT process are required.
Practitioner's Observation: Objective Notes on Third-Generation IVF at Naren Hospital
As a doctor with many years of experience in the assisted reproduction field, I believe three points need emphasis: First, Naren Hospital's PGT laboratory is certified by the Thai Ministry of Public Health (MOPH), and its technical processes align with international standards, but this does not mean all patients will succeed. Second, the technical threshold for third-generation IVF lies primarily in the laboratory, not the clinical side. The hospital's embryology team has sufficient experience in blastocyst biopsy, but patients should still request to see the laboratory's quality control data (e.g., blastocyst formation rate, post-biopsy survival rate, test result turnaround time). Third, any medical decision should be based on a complete personal medical history, not solely on a hospital's name or technical label. It is advisable to complete a video or in-person genetic counseling session before deciding.
Suggestions for Next Steps
If you are considering third-generation IVF at Naren Hospital, my advice is: First, complete genetic counseling and expanded carrier screening (ECS) for both partners to determine if there are clear PGT indications. Then, schedule an initial consultation through the hospital's official channels, submit previous reports, and obtain a personalized cycle plan and cost breakdown. Before starting ovarian stimulation, confirm the laboratory's testing turnaround time and biopsy experience, and discuss backup plans with your doctor for scenarios like "no transferable embryos" (e.g., egg donation, embryo donation, or attempting natural conception).
